ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

ClinicalTrials.gov ID: NCT04644770

Public ClinicalTrials.gov record NCT04644770. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Study identification

NCT ID
NCT04644770
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
144 participants

Conditions and interventions

Interventions

  • JNJ-69086420 Drug
  • JNJ-78278343 Drug
  • Stereotactic body radiation therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 11, 2020
Primary completion
Jan 14, 2027
Completion
Jan 14, 2027
Last update posted
Apr 12, 2026

2020 – 2027

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Mayo Clinic Arizona Phoenix Arizona 85054
City of Hope Duarte California 91010
Mayo Clinic in Florida Jacksonville Florida 32224
University of Chicago Chicago Illinois 60637
East Jefferson General Hospital Metairie Louisiana 70006
Tulane University Hospital & Clinics New Orleans Louisiana 70112
Mayo Clinic Rochester Rochester Minnesota 55905
XCancer Omaha / Urology Cancer Center Omaha Nebraska 68130
Memorial Sloan Kettering Cancer Center New York New York 10065
Case Western Reserve University Cleveland Ohio 44106
University of Utah Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04644770, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04644770 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →